Table 1.
Exp. | Recipient* | Donor
|
Specific lysis of targets, (%)
|
||||
---|---|---|---|---|---|---|---|
Thymus | Bone marrow- derived cells | MC57 (H-2b) | P185 (H-2d) | ||||
LCMV | Uninf. | p118 | Uninf. | ||||
1 | Nude (H-2b × H-2d) | H-2b | None | 84 | 4 | 15 | 6 |
(C57BL/6 × BALB/c) F1 | RAG0/0 | 74 | 3 | 5 | 7 | ||
H-2d | None | 19 | 10 | 64 | 6 | ||
SCID | 11 | 1 | 70 | 3 | |||
H-2d | None | 2 | 2 | 56 | 1 | ||
RAG0/0 | <1 | <1 | 46 | 2 | |||
MC57 (H-2b) | L929 (H-2k) | ||||||
2 | Nude (H-2b) C57BL/6 (>95%) | H-2k | None (<8%) | 69 | 7 | 14 | 15 |
RAG0/0 | 52 | 5 | 11 | 12 | |||
35 | 1 | 7 | 7 | ||||
24 | 2 | 5 | 4 | ||||
Nude (H-2b) C57BL/6 (>95%) | H-2k | None | 99 | 14 | 19 | 25 | |
RAG0/0 | 77 | 7 | 12 | 14 | |||
42 | 1 | 4 | 14 | ||||
32 | 3 | 3 | 17 | ||||
Nude (H-2b) C57BL/6 (60%) | H-2k | H-2k (40%) | 23 | 35 | 70 | 19 | |
RAG0/0 | RAG0/0 | 14 | 11 | 74 | 22 | ||
7 | 5 | 69 | 14 | ||||
9 | 2 | 44 | 8 | ||||
Nude (H-2b) C57BL/6 (50%) | H-2k | H-2k (50%) | 68 | 11 | 71 | 35 | |
RAG0/0 | RAG0/0 | 49 | 5 | 67 | 24 | ||
27 | 3 | 60 | 16 | ||||
12 | 1 | 44 | 12 | ||||
Controls: | |||||||
C3H (H-2k) | 16 | 12 | 76 | 30 | |||
C57BL/6 (H-2b) | 97 | 9 | 32 | 27 |
The data shown are representative for three comparable experiments for Exp. 1, a total of four to eight mice each tested in Exp. 2 and 3. uninf., uninfected.
Mice were infected with 102 pfu of LCMV; 7 or 8 days later, CTL activity was tested in a 5-h assay on the indicated targets at spleen cell-to-target cell ratios of 90, 30, 10, or 3:1 [except for Exp. 1 and controls, where only 90 and 30 or 90 are shown (top to bottom)]. Bold values are significant above relevant controls (p < 0.1). Numbers in parentheses are % of lymphocytes of the indicated H-2.